Customize your search results with filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.

Journal: Current treatment options in oncology
Published: October 25, 2021
View publication
Summary: Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.

Therapeutic algorithm of Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma in Japan.

Journal: The Japanese journal of clinical hematology
Published: September 09, 2021
View publication
Summary: Therapeutic algorithm of Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma in Japan.

How to Sequence Therapies in Waldenström Macroglobulinemia.

Condition: Waldenström Macroglobulinemia
Journal: Current treatment options in oncology
Treatment Used: Chemotherapy, Monoclonal Antibodies, Proteasome Inhibitors, and Covalent Bruton Tyrosine Kinase (BTK) inhibitors
Number of Patients: 0
Published: August 24, 2021
View publication
Summary: This article discusses multiple treatment options for patients with Waldenström macroglobulinemia.

Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.

Journal: Frontiers in immunology
Published: June 28, 2021
View publication
Summary: Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.

Nodal lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia: a clinicopathological and prognostical study.

Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology
Published: June 03, 2021
View publication
Summary: Nodal lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia: a clinicopathological and prognostical study.

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia.

Condition: Waldenström Macroglobulinemia
Journal: Blood advances
Treatment Used: Obinutuzumab plus Idelalisib
Number of Patients: 75
Published: May 07, 2021
View publication
Summary: This study evaluated the safety and effectiveness of obinutuzumab plus idelalisib in patients with relapsed (recurring)/refractory (resistant to treatment) Waldenström macroglobulinemia (rare type of cancer that begins in the white blood cells).

A study of LEF1 protein expression in diagnosis and differential diagnosis of lymphoblastic lymphoma/acute lymphoblastic leukemia.

Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology
Published: March 07, 2021
View publication
Summary: A study of LEF1 protein expression in diagnosis and differential diagnosis of lymphoblastic lymphoma/acute lymphoblastic leukemia.

Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.

Condition: MYD88 Wild-Type Waldenstrom Macroglobulinemia (WM)
Journal: Blood advances
Treatment Used: Zanubrutinib
Number of Patients: 28
Published: December 07, 2020
View publication
Summary: This study evaluated zanubrutinib for the treatment of MYD88 wild-type Waldenstrom macroglobulinemia (type of cancer affecting two types of B cells; WM).

Rheumatic involvement and bone scan features in Schnitzler syndrome: initial and follow-up data from a single-center cohort of 25 patients.

Journal: Arthritis research & therapy
Published: November 19, 2020
View publication
Summary: Rheumatic involvement and bone scan features in Schnitzler syndrome: initial and follow-up data from a single-center cohort of 25 patients.

Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.

Condition: Treatment-Naive Patients with Waldenström Macroglobulinemia
Journal: Blood advances
Treatment Used: Ixazomib, Dexamethasone, and Rituximab (IDR)
Number of Patients: 26
Published: August 22, 2020
View publication
Summary: This study evaluated the combination of ixazomib, dexamethasone, and rituximab (IDR) in treatment-naive patients with Waldenström macroglobulinemia (B-cell lymphoma subtype; WM).

Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.

Condition: Extramedullary Waldenstrom's Macroglobulinemia
Journal: Journal of medical case reports
Treatment Used: Ibrutinib
Number of Patients: 1
Published: July 14, 2020
View publication
Summary: This case report describes a 72-year-old Caucasian man diagnosed with extramedullary Waldenstrom's macroglobulinemia (lymphatic disease) treated with ibrutinib.

A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia.

Condition: Waldenstom's Macroglobulinemia (WM)
Journal: Cancer science
Treatment Used: Tirabrutinib
Number of Patients: 27
Published: July 09, 2020
View publication
Summary: This study evaluated the effectiveness and safety of tirabrutinib in patients with Waldenstrom's macroglobulinemia (type of cancer that begins in the white blood cells; WM).
Showing 1-12 of 27